^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    NCAPD2 (Non-SMC Condensin I Complex Subunit D2)

    i
    Other names: NCAPD2, Non-SMC Condensin I Complex Subunit D2, HCAP-D2, CNAP1, KIAA0159, CAP-D2, Chromosome Condensation-Related SMC-Associated Protein 1, Chromosome-Associated Protein D2, Condensin Complex Subunit 1, XCAP-D2 Homolog, Chromosome Condensation Related SMC Associated Protein 1, Non-SMC Condensin I Complex, Subunit D2, MCPH21, CAPD2
    Associations

    News

    Trials
    3ms
    Molecular Resonance Quantification and Label-Free Interactome Characterization of Total Proteome of Tumor Specimens Decipher Responder and Success Predictors in Colorectal Cancer Patients Treated With Panitumumab. (PubMed, Cancer Med)
    Combination of PIMS and NPOT coupled to label-free quantitative proteomics point towards the distinct panitumumab mode of action in CRC patients and highlights specific proteins as prognostic biomarkers which need further validation in a bigger cohort and multicentric investigation, ideally involving patient registry follow up data.
    Journal
    |
    CTNNB1 (Catenin (cadherin-associated protein), beta 1) • POLD1 (DNA Polymerase Delta 1) • PTPN1 (Protein Tyrosine Phosphatase Non-Receptor Type 1) • ENO1 (Enolase 1) • YBX1 (Y-Box Binding Protein 1) • CTNND1 (Catenin Delta 1) • ITGB2 (Integrin Subunit Beta 2) • LRIG1 (Leucine Rich Repeats And Immunoglobulin Like Domains 1) • NT5C (5', 3'-Nucleotidase, Cytosolic) • PRKDC (Protein Kinase, DNA-Activated, Catalytic Subunit) • HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1) • HSP90AB1 (Heat Shock Protein 90 Alpha Family Class B Member 1) • HSPA4 (Heat Shock Protein Family A (Hsp70) Member 4) • ITGB1 (Integrin Subunit Beta 1) • PPM1G (Protein Phosphatase, Mg2+/Mn2+ Dependent 1G) • YWHAZ (Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Zeta) • HSPA8 (Heat Shock Protein Family A (Hsp70) Member 8) • NCAPD2 (Non-SMC Condensin I Complex Subunit D2)
    |
    Vectibix (panitumumab)
    3ms
    NCAPD2 promotes the progression of lung adenocarcinoma through an AKT/MDM2/E2F1 positive feedback loop. (PubMed, Cancer Biol Ther)
    This study reveals a novel role of NCAPD2 in promoting LUAD progression through the AKT/MDM2/E2F1 positive feedback loop. These findings provide new insights into the molecular pathogenesis of LUAD and suggest NCAPD2 as a potential therapeutic target for improving patient outcomes.
    Journal
    |
    E2F1 (E2F transcription factor 1) • NCAPD2 (Non-SMC Condensin I Complex Subunit D2)
    5ms
    NCAPD2 Modulates MHC-I Antigen Presentation via the PI3K/AKT Axis to Drive Metastatic Progression in Gastric Cancer. (PubMed, Dig Dis Sci)
    In GC, elevated NCAPD2 expression is a negative prognostic marker associated with advanced tumor stage and poorer survival. Functionally, NCAPD2 promotes malignant phenotypes and downregulates MHC-I antigen presentation via the PI3K/AKT pathway, thereby facilitating immune evasion. These findings suggest NCAPD2 as a potential therapeutic target in GC.
    Journal
    |
    NCAPD2 (Non-SMC Condensin I Complex Subunit D2)
    |
    LY294002
    5ms
    NCAPD2 stimulates glycolysis and esophageal cancer metastasis through Wnt5A-dependent Notch activation. (PubMed, Cell Signal)
    NCAPD2 enhanced the proliferation and metastasis of EC cells by promoting glycolysis through Wnt5A-mediated activation of the Notch pathway. This finding not only revealed the critical role of the NCAPD2/Wnt5A axis in EC but also provided a potential therapeutic target for EC treatment.
    Journal
    |
    WNT5A (Wnt Family Member 5A) • NCAPD2 (Non-SMC Condensin I Complex Subunit D2)
    6ms
    Identifying genes associated with Sorafenib resistance in hepatocellular carcinoma to develop risk model. (PubMed, Discov Oncol)
    This study provides a comprehensive framework for understanding sorafenib resistance in HCC, alongside a validated prognostic model that holds potential for clinical application.
    Journal
    |
    CDK5RAP2 (CDK5 Regulatory Subunit Associated Protein 2) • KIF2C (Kinesin Family Member 2C) • LPCAT1 (Lysophosphatidylcholine Acyltransferase 1) • NCAPD2 (Non-SMC Condensin I Complex Subunit D2)
    |
    sorafenib
    8ms
    Prognostic and immunotherapeutic significance of NCAPD2 in pan-cancer and its role in hepatocellular carcinoma progression via the AKT/GSK-3β signaling pathway. (PubMed, Sci Rep)
    In conclusion, NCAPD2 is a potential diagnostic and prognostic marker in pan-cancer, particularly for HCC. It promotes tumor progression through the AKT/GSK-3β pathway and influences immune infiltration, offering insights for immunotherapy and precision medicine strategies in HCC.
    Journal • IO biomarker • Pan tumor
    |
    MSI (Microsatellite instability) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • NCAPD2 (Non-SMC Condensin I Complex Subunit D2)
    10ms
    Impact of Non-SMC Condensin I Complex Subunit D2 Upregulation on Oral Squamous Cell Carcinoma Prognosis. (PubMed, Int Dent J)
    NCAPD2 is a potential molecular marker for the poor prognosis of OSCC, and it is expected to become a target for the treatment of this carcinoma.
    Journal
    |
    NCAPD2 (Non-SMC Condensin I Complex Subunit D2)
    over1year
    The causal nexus between diverse smoking statuses, potential therapeutic targets, and NSCLC: insights from Mendelian randomization and mediation analysis. (PubMed, Front Oncol)
    Utilizing NCAPD2, IL11RA, and MLC1 as mediators, IL11RA (22.2%) was found to potentially mediate the relationship between past tobacco smoking and NSCLC. This study, integrating bioinformatics and MR analysis, identified three potential predictive targets as mediators to investigate the causal relationships between different smoking statuses and NSCLC through potential therapeutic targets, providing new insights for the treatment and prevention of NSCLC.
    Journal
    |
    IL1R1 (Interleukin 1 receptor, type I) • NCAPD2 (Non-SMC Condensin I Complex Subunit D2)
    over1year
    NCAPD2 serves as a potential prognostic biomarker for lung adenocarcinoma and promotes cell proliferation, migration, invasion and cell cycle in vitro. (PubMed, Oncol Res)
    In vitro experiments demonstrated that silencing NCAPD2 suppressed LUAD cell proliferation, migration, invasion, epithelial-mesenchymal transition (EMT), and cell cycle progression. In summary, NCAPD2 may represent a promising prognostic biomarker and novel therapeutic target for LUAD.
    Preclinical • Journal
    |
    CD4 (CD4 Molecule) • NCAPD2 (Non-SMC Condensin I Complex Subunit D2)
    over1year
    NCAPD2 augments the tumorigenesis and progression of human liver cancer via the PI3K‑Akt‑mTOR signaling pathway. (PubMed, Int J Mol Med)
    In addition, upregulated NCAPD2 was shown to have adverse effects on overall survival and disease‑specific survival in liver cancer. In conclusion, the overexpression of NCAPD2 was shown to lead to cell cycle progression at the G2/M‑phase transition, activation of the PI3K‑Akt‑mTOR/c‑Myc signaling pathway and EMT progression in human liver cancer cells.
    Journal
    |
    NCAPD2 (Non-SMC Condensin I Complex Subunit D2)
    almost2years
    NCAPD2 promotes the malignant progression of oral squamous cell carcinoma via the Wnt/β-catenin pathway. (PubMed, Cell Cycle)
    Mechanically, OSCC regulation by NCAPD2 involved the Wnt/β-catenin signaling pathway. These results suggest NCAPD2 as a novel oncogene with an important role in OSCC development and a candidate therapeutic target for OSCC.
    Journal
    |
    NCAPD2 (Non-SMC Condensin I Complex Subunit D2)